The effect of risedronate (17.5 mg/week) treatment on quality of life in Japanese women with osteoporosis: a prospective observational study
Journal of Bone and Mineral Metabolism, 08/21/2012
Nakamura T et al. – Risedronate at 17.5 mg/week improved the quality of life in patients with osteoporosis among Japanese women, and comorbidity factors decreased the effects.Methods
- A prospective observational study to test the effects of risedronate 17.5 mg/week treatment on quality of life (QOL) of 1,363 Japanese female patients with osteoporosis showed QOL improvement after 12 weeks of administration.
- Comorbid factors such as ischemic heart disease, hip osteoarthritis, and higher values of FRAX blunted the effects of QOL of the treatment.
- Few studies have investigated the effect of osteoporosis treatment on QOL in relationship to comorbid factors other than osteoporosis and fracture.
- Efficacy was determined by changes over time in EQ–5D at baseline, at 12 and 24 weeks, and at the final assessment.
- Factors affecting changes in EQ–5D were evaluated with a multivariate analysis.
- Safety was determined by assessing the incident rate of adverse events.
- The improvement of EQ–5D compared to baseline was observed as significant after 12 weeks of treatment (p < 0.001).
- The greatest improvement was observed in the dimension of “pain/discomfort” by the multivariate analysis (p < 0.001).
- Factors affecting QOL improvement were FRAX value without BMD, age, glucocorticoid use, ischemic heart disease, hip osteoarthritis, and pain.
- The incidence rate of drug–related adverse events was 4.72 % (95 % confidence interval 3.63–6.02 %).